DeGette, Bucshon Lead Bipartisan Push to Improve Diagnostic Testing
WASHINGTON – Reps. Diana DeGette, D-Colo., and Dr. Larry Bucshon, R-Ind., are leading a renewed bipartisan drive to improve the nation’s diagnostic testing capabilities and ensure hospitals and laboratories across the country are better able to respond to future national health emergencies, such as the COVID-19 pandemic.
The legislation is known as the Verifying Accurate, Leading-edge IVCT Development, or VALID, Act. An identical version of the bill – sponsored by Sens. Michael Bennet, D-Colo., and Richard Burr, R-N.C., has been introduced in the Senate.
It would, among other things, permanently lift a Food and Drug Administration requirement that all diagnostic tests used to screen patients during a declared public health emergency be approved by the agency before they are used to diagnose the emerging threat.
Instead, under the terms of the bill, hospitals and labs that have validated their tests – and provided that data to FDA – would be able to start using them immediately to screen patients as FDA considers their application for emergency use.
The legislation also seeks to address concerns raised by public health officials in the early stages of the pandemic that the FDA policy in place at the outset of the pandemic impeded their ability to quickly and efficiently respond to the virus and, when necessary, quarantine those who had become infected.
“If we’ve learned anything from combating the spread of highly contagious viruses – such as MERS, SARS, Ebola and now COVID-19 – it’s that time is of the essence,” DeGette said. “We can’t allow an outdated and inefficient system to hold us back when trying to respond to an emerging threat, such as the coronavirus.
“This legislation will ensure that our hospitals and laboratories have the ability to respond quickly, accurately and efficiently to help us detect and stop the spread of these diseases before it’s too late,” she said.
In addition to removing the FDA’s pre-approval requirement for tests used to screen patients during future public health emergencies, DeGette and Bucshon’s legislation would completely overhaul how the federal government reviews and approves all diagnostic tests going forward.
Among other things, it would create an entirely new product category for diagnostic and lab tests, putting their review and approval squarely under the FDA.
It would also create a new system that would allow hospitals and labs to submit their tests to the FDA electronically, a change that would improve the agency’s ability to oversee their quality and reliability, while at the same time drastically reducing the time it takes the agency to review them.
Additionally, the VALID Act would establish a program to expedite the development and review of new diagnostic tests that seek to address a current unmet need for patients. And it includes a provision to grandfather in any tests currently available to patients in the U.S. so it doesn’t – in any way – impede the ability of health care providers to continue testing and treating patients as they are today.
Diagnostic tests are an important tool used by health care providers across the U.S. to make sometimes difficult decisions about the best course of care and treatment for their patients. The accuracy and reliability of such tests can literally mean the difference between life and death for some patients.
